Effects of gender-affirming hormone therapy on lower urinary tract symptoms and sexual function among transgender individuals.

Objective: Gender-affirming hormone therapy (GAHT) includes estrogen preparations and androgen inhibitors for transgender women, and testosterone preparations for transgender men. The aim of the study was to investigate possible effects of GAHT on lower urinary tract symptoms (LUTS) and sexual function among transgender individuals.

Methods: Fifty-one transgender men and 47 transgender women were prospectively recruited.